Impact of duration of bone-targeting agent on adverse events (AEs) and skeletal-related events (SRE) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): Real-world experience from Princess Margaret Cancer Centre (PM).
Year: 2026
Type: conference-abstract
Study design: Observational Study
Source: Journal of Clinical Oncology
Authors: Ealia Khosh Kish, Arman Zereshkian, Manjula Maganti, Patrick Veit-Haibach, Antonio Finelli, Neil Eric Fleshner, John Trachtenberg, Nathan Perlis, Alejandro Berlin, Andrew Bayley, Charles Catton, Peter W. M. Chung, Padraig Warde, Sheeraz Ali, Vikaash Kumar, Esmail Mutahar Al-Ezzi, Nazanin Fallah-Rad, Srikala S. Sridhar, Di Maria Jiang
Language: English
Topic: Bone health and treatments
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162689665
Cites:
Cited by:
Related to: